计算溶液所需的质量、体积或浓度。
Pramipexole 2HCl Monohydrate 是一种部分/全部D2S, D2L, D3, D4受体激动剂,Ki为3.9, 2.2, 0.5, 5.1 nM。A non-ergoline dopamine agonist.
Information
Pramipexole 2HCl Monohydrateis a novel non-ergoline dopamine (DA) agonist, used to treat Parkinson's disease.
In vitro
Pramipexole, a chemically novel dopamine agonist used for the treatment of Parkinson\'s disease symptoms, possesses antioxidant activity and is neuroprotective toward substantia nigral dopamine neurons in hypoxic-ischemic and methamphetamine models. Pramipexole reduces the levels of oxygen radicals produced by methylpyridinium ion (MPP+) both when incubated with SH-SY5Y cells and when perfused into rat striatum. Pramipexole also exhibits a concentration-dependent inhibition of opening of the mitochondrial transition pore induced by calcium and phosphate or MPP+. Pramipexole decreases the levels of dopamine metabolites dose dependently, whereas striatal dopamine levels remains unchanged. Pramipexole acts in both of these models to reduce the elevated dopamine turnover and the associated elevation in hydroxyl radical production secondary to increased MAO activity that could be responsible for oxidative damage to the nigrostriatal neurons. Pramipexole (4-100 mM) significantly attenuates DA- or L-DOPA-induced cytotoxicity and apoptosis, an action which is not blocked by D3 antagonist U-99194 A or D2 antagonist raclopride. Pramipexole also protects MES 23.5 cells from hydrogen peroxide-induced cytotoxicity in a dose-dependent manner. Pramipexole can effectively inhibit the formation of melanin, an end product resulting from DA or L-DOPA oxidation in cell-free system.
In vivo
Pramipexole (0.001-1 mg/kg s.c.) reduces exploratory locomotor activity in mice. Pramipexole (1 mg/kg, p.o.) is able to significantly reduce the increased DA turnover, but by only 16%.
Cell Data
cell lines:
Concentrations:
Incubation Time:
Powder Purity:≥99%
H302: 吞食有害
H317: 可能引起皮肤过敏反应